About TPR and ankyrin repeat-containing protein 1
TPR and ankyrin repeat-containing protein 1 (TRANK1) is a protein
from Homo sapiens identified by UniProt accession
O15050, 2925 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | TPR and ankyrin repeat-containing protein 1 |
|---|
| UniProt accession | O15050 |
|---|
| Gene | TRANK1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2925 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (92)
Diseases linked to this target (Open Targets).
- autism spectrum disorder · score 0.50
- schizophrenia · score 0.47
- bipolar disorder · score 0.45
- mean platelet volume · score 0.43
- high density lipoprotein cholesterol measurement · score 0.43
- self reported educational attainment · score 0.41
- electrocardiography · score 0.39
- Lynch syndrome · score 0.36
- alkaline phosphatase measurement · score 0.32
- pulse pressure measurement · score 0.32
3D Structure (9)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (2925 residues)
MWDPRAARVP PRDLAVLLCN KSNAFFSLGK WNEAFVAAKE CLQWDPTYVK GYYRAGYSLL RLHQPYEAAR MFFEGLRLVQ RSQDQAPVAD FLVGVFTTMS SDSIVLQSFL PCFDHIFTTG FPTEVWQSVI EKLAKKGLWH SFLLLSAKKD RLPRNIHVPE LSLKSLFEKY VFIGLYEKME QVPKLVQWLI SIGASVETIG PYPLHALMRL CIQARENHLF RWLMDHKPEW KGRINQKDGD GCTVLHVVAA HSPGYLVKRQ TEDVQMLLRF GADPTLLDRQ SRSVVDVLKR NKNFKAIEKI NSHLEKLATC SKDLSGFSNG DGPTSENDIF RKVLEQLVKY MNSGNRLLHK NFLKQEVVQR FLRLLSTLQE IPPDLVCDIN QDCATTVFKF LLEKQRWPEV LLLLTRKVSG EPPLGDCLIK DCNFSDLDIC TIIPHLSTWD QRKKQLLGCL IDSGALPDGL QESQERPVVT CLKHEDFELA FLLLTKGADP RAISLTEGDT PLHAALHIFL EIKADIGFSF LSHLLDLFWS NPTEFDYLNP NVQDSNGNTL MHILFQKGML KRVKKLLDLL VKFDINFNLK NKEGKDARHR IKKNDSLLLA WNKALMENRR RSRQDSAAHL GKLSKSTAPG HTSQLKSQGS FKSVPCGATA RTLPEGSAVP DSWETLPGTQ VTRKEPGALR PCSLRDCLMQ DITVLIQQVE VDPSFPEDCL QSSEPLEAGA GKEGKKDDKP TLGAGAPDCS EVGEGHAQVG LGALQLVPDD NRGKEGNDDQ DDWSTQEIEA CLQDFDNMTW EIECTSEMLK KLSSKVMTKV IKKKIILAIQ QLGNGEWTQG LQKRLKHLKG SIQLFEAKLD KGARMLWELA IDFSPRCSEN PEKIIATEQN TCAMEKSGRI YTEIIRIWDI VLDHCKLADS IKAICNAYNR GLSCVLRKKL KGINKGQVSA NMKIQKRIPR CYVEDTEAEK GREHVNPEYF PPASAVETEY NIMKFHSFST NMAFNILNDT TATVEYPFRV GELEYAVIDL NPRPLEPIIL IGRSGTGKTT CCLYRLWKKF HVYWEKAEQA GSPLLAKQVW LKRRLEVEPG KESPGGEEEE EEEDEEEEDS IEVETVESID EQEYEACAGG AGVEPAGDGQ AAEVCAPEHP HQLEHLHQIF VTKNHVLCQE VQRNFIELSK STKATSHYKP LDPNIHKLQD LRDENFPLFV TSKQLLLLLD ASLPKPFFLR NEDGSLKRTI IGWSAQEEST IPSWQEDEEE AEVDGDYSEE DKAVEMRTGD SDPRVYVTFE VFKNEIWPKM TKGRTAYNPA LIWKEIKSFL KGSFEALSCP HGRLTEEVYK KLGRKRCPNF KEDRSEIYSL FSLYQQIRSQ KGYFDEEDVL YNISRRLSKL RVLPWSIHEL YGDEIQDFTQ AELALLMKCI NDPNSMFLTG DTAQSIMKGV AFRFSDLRSL FHYASRNTID KQCAVRKPKK IHQLYQNYRS HSGILNLASG VVDLLQFYFP ESFDRLPRDS GLFDGPKPTV LESCSVSDLA ILLRGNKRKT QPIEFGAHQV ILVANETAKE KIPEELGLAL VLTIYEAKGL EFDDVLLYNF FTDSEAYKEW KIISSFTPTS TDSREENRPL VEVPLDKPGS SQGRSLMVNP EMYKLLNGEL KQLYTAITRA RVNLWIFDEN REKRAPAFKY FIRRDFVQVV KTDENKDFDD SMFVKTSTPA EWIAQGDYYA KHQCWKVAAK CYQKGGAFEK EKLALAHDTA LSMKSKKVSP KEKQLEYLEL AKTYLECKEP TLSLKCLSYA KEFQLSAQLC ERLGKIRDAA YFYKRSQCYK DAFRCFEQIQ EFDLALKMYC QEELFEEAAI AVEKYEEMLK TKTLPISKLS YSASQFYLEA AAKYLSANKM KEMMAVLSKL DIEDQLVFLK SRKRLAEAAD LLNREGRREE AALLMKQHGC LLEAARLTAD KDFQASCLLG AARLNVARDS DIEHTKDILR EALDICYQTG QLSGIAEAHF LQGVILRDFQ KLRDAFFKFD TLNHSAGVVE ALYEAASQCE AEPEKILGLA PGGLEILLSL VRALKRVTNN AEKEMVKSCF EFFGISQVDA KYCQIAQNDP GPILRIIFDL DLNLREKKTK DHFLIMTDQV KLALNKHLLG RLCQITRSLL GKTYRGVCMR FIVGLKCEDE NCEHFHRPLR RCEAKCLVQS KMNLVAINGL LLEAKKVFPK ILAEELKEID YILSTDMYGL CKSILDVLFP KHFHQRVLSE NPMACKEILK PNYKSFRFYR FALKEYIHFL FENESARNRR ESTDLWLSAM QAFLLSSNYP EEFEKLLHQE EDNYNRELKA LESEKDERGR GRGSRIKGIE GKFGMLAPNR DDENMDKTHL CFIRLLENCI DQFYVYRNPE DYKRLFFRFM NVLIKRCKEP LIPSIGNTVA LLEFQFIHCG VVLARLWKNV ILCLPKSYIA LLHYWEFLFS KKDKELGDVF SIIQEYKPKD VTRAIQDFRF HLSYLAKVLC GYENVNFNVL LDAFSEIDYV VSGEAERTLV LCLVMLVNAE EILQPYCKPL LYRHFREIES RLQLMSMDCP GQVPERLLKV VKRVLVAVNV KSVAEALQDL LFERDEEYLM DCDWRWDPVH TKGSIVRGLY YEEVRLNRLL CLDPVDYFAE PECEFGQDEM DELALEDRDH VLATILSQKQ RKASIQRKLR RACLVVSLCI SWRRRVGTQM ERVREEAREP RAGNFKKADV DRTQCDLCGV KFTRGPENYF SPSKAFEGAA SEVAVLSRAE LEREECQERN SESYEQHIHL EHHQRQQVAY QKYSEFFHEK VDPAIDEGKL VVQDIEQSVW IHSHVGSKEH SHMLQKVQEH IKRVSDMVED LYRRKAWAGA EEAMTRLVNI LILSVRDARD WLMKTETRLK KEGIVQEDDY ENEVEDFGEL RPRRRSRKCG KQRKY
Explore TPR and ankyrin repeat-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets